Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively. In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. AG1343 (Viracept) has recently been approved for marketing for the treatment of AIDS.

[1]  M. Boyd,et al.  New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. , 1989, Journal of the National Cancer Institute.

[2]  A. Freeman,et al.  Studies toward the Large-Scale Synthesis of the HIV Proteinase Inhibitor Ro 31-8959 , 1994 .

[3]  K. Appelt,et al.  Crystal structures of HIV-1 protease-inhibitor complexes , 1993 .

[4]  J. Huff,et al.  HIV protease: a novel chemotherapeutic target for AIDS. , 1991, Journal of medicinal chemistry.

[5]  P. Darke,et al.  HIV protease as an inhibitor target for the treatment of AIDS. , 1994, Advances in pharmacology.

[6]  K. Appelt,et al.  Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[8]  K. Appelt,et al.  Isophthalic acid derivatives: amino acid surrogates for the inhibition of HIV-1 protease , 1995 .

[9]  J. Vederas,et al.  Conversion of serine to stereochemically pure .beta.-substituted .alpha.-amino acids via .beta.-lactones , 1985 .

[10]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[11]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Redshaw,et al.  Studies Toward the Large-Scale Synthesis of the HIV Proteinase Inhibitor Ro 31-8959. , 1994 .

[14]  K. Appelt,et al.  Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series. , 1996, Journal of medicinal chemistry.